肿瘤药学2025，Vol.15Issue(2)：252-258,7.DOI:10.3969/j.issn.2095-1264.2025.02.14
基于倾向性评分匹配的PD-1抑制剂相关甲状腺不良事件危险因素分析
Analysis of risk factors of PD-1 inhibitor-associated thyroid adverse events based on propensity score matching
摘要
Abstract
Objective To analyze the risk factors of PD-1 inhibitor-related thyroid adverse events,so as to provide a ba-sis for reducing the risk of related adverse events.Methods A total of 252 hospitalized patients who received PD-1 inhibi-tors from January 2020 to October 2023 were included,comprising 106 cases with thyroid adverse events and 146 cases with normal thyroid function.A 1∶1 propensity score matching(PSM)was used to balance confounding factors between groups,and logistic regression analysis was performed to identify risk factors.Results The incidence of thyroid adverse events was 42.1%(106/252),with 20.7%(22/106)presenting significant clinical symptoms,and 2 cases(1.9%)requiring temporary treatment discontinuation.After PSM,78 matched case pairs were successfully analyzed.Univariate analysis showed significant differences between the two groups in terms of comorbidities,concurrent chemotherapy,and concurrent targeted therapy(P<0.05).Multivariate logistic regression analysis revealed that the comorbidities,concurrent chemothera-py,and concurrent targeted therapy were independent risk factors for PD-1 inhibitor-associated thyroid adverse events(P<0.05).Conclusion Although PD-1 inhibitor-related thyroid adverse events are mostly mild and rarely disrupt treatment,patients with comorbidities,those receiving concurrent chemotherapy,or those treated with TKI-based targeted therapy re-quire enhanced thyroid function monitoring.关键词
PD-1抑制剂/甲状腺不良事件/倾向性评分匹配/混杂因素/危险因素Key words
PD-1 inhibitors/Thyroid adverse event/Propensity score matching/Confounding factors/Risk factors分类
临床医学引用本文复制引用
汪祝青,吴怡青,朱忠华..基于倾向性评分匹配的PD-1抑制剂相关甲状腺不良事件危险因素分析[J].肿瘤药学,2025,15(2):252-258,7.基金项目
2023年安徽省临床医学研究转化专项项目(202304295107020090). （202304295107020090）
